A clinical study of a cell-based MAGE-A3 active immunotherapy in advanced melanoma patients

Vincenzo Russo; Francesca Lunghi; Raffaella Fontana; Marco Bregni

doi:10.7150/jca.2.329

A clinical study of a cell-based MAGE-A3 active immunotherapy in advanced melanoma patients

Vincenzo Russo, Francesca Lunghi, Raffaella Fontana, Marco Bregni

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3⁺ melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were as-sessed by in vitro assay and delayed-type hypersensitivity skin testing.

Original language	English
Pages (from-to)	329-330
Number of pages	2
Journal	Journal of Cancer
Volume	2
Issue number	1
DOIs	https://doi.org/10.7150/jca.2.329
Publication status	Published - 2011

Keywords

Immunotherapy
MAGE-A3
Melanoma

ASJC Scopus subject areas

Oncology

Access to Document

10.7150/jca.2.329

Cite this

@article{990ac93f6d464d13bf0a74f611aa6405,

title = "A clinical study of a cell-based MAGE-A3 active immunotherapy in advanced melanoma patients",

abstract = "In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3+ melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were as-sessed by in vitro assay and delayed-type hypersensitivity skin testing.",

keywords = "Immunotherapy, MAGE-A3, Melanoma",

author = "Vincenzo Russo and Francesca Lunghi and Raffaella Fontana and Marco Bregni",

year = "2011",

doi = "10.7150/jca.2.329",

language = "English",

volume = "2",

pages = "329--330",

journal = "Journal of Cancer",

issn = "1837-9664",

publisher = "Ivyspring International Publisher",

number = "1",

}

TY - JOUR

T1 - A clinical study of a cell-based MAGE-A3 active immunotherapy in advanced melanoma patients

AU - Russo, Vincenzo

AU - Lunghi, Francesca

AU - Fontana, Raffaella

AU - Bregni, Marco

PY - 2011

Y1 - 2011

N2 - In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3+ melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were as-sessed by in vitro assay and delayed-type hypersensitivity skin testing.

AB - In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3+ melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were as-sessed by in vitro assay and delayed-type hypersensitivity skin testing.

KW - Immunotherapy

KW - MAGE-A3

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=84869881033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869881033&partnerID=8YFLogxK

U2 - 10.7150/jca.2.329

DO - 10.7150/jca.2.329

M3 - Article

AN - SCOPUS:84869881033

VL - 2

SP - 329

EP - 330

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 1

ER -

A clinical study of a cell-based MAGE-A3 active immunotherapy in advanced melanoma patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this